1. Камкин Е.Г., Костенко Н.А., Каракулина Е.В. и др. Профилактика, диагностика и лечение новой коронавирусной инфекции (COVID-19). Временные методические рекомендации. М.: Министерство Здравоохранения Российской Федерации, 2020. Версия 6. 164 с.
2. Статистика по заболеваемости новой коронавирусной инфекцией в России, 2020. Доступно по: https://стопкоронавирус.рф (дата обращения 22.05.2020).
3. Liang W., Guan W., Chen R. et al. Cancer Patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol 2020;21(3):335–7. DOI: 10.1016/S1470-2045(20)30096-6.
4. Dai M., Liu D., Miao Liu M. et al. Patients with cancer appear more vulnerable to SARS-COV-2: a multicenter study during the COVID-19 outbreak. Cancer Discov 2020. DOI: 10.1158/2159-8290.CD-20-0422.
5. COVID-19 Registry for Hematological Malignancy Data Summaries. ASH RC Data Hub, 2020. Available at: https://www.ashresearchcollaborative.org/s/covid-19registry-data-summaries.
6. Blimark C., Holmberg E., Mellqvist U.H. et al. Multiple myeloma and infections: a population-based study on 9253 multiple myeloma patients. Haematologica 2015;100(1):107–13. DOI: 10.3324/haematol.2014.107714.
7. Heider U., Rademacher J., Kaiser M. et al. Decrease in CD4+ T-cell counts in patients with multiple myeloma treated with bortezomib. Clin Lymphoma Myeloma Leuk 2010;10(2):134–7. DOI: 10.3816/CLML.2010.n.019.
8. Ying L., YinHui T., Yunliang Z., Sun H. Lenalidomide and the risk of serious infection in patients with multiple myeloma: a systematic review and meta-analysis. Oncotarget 2017;8(28):46593–600. DOI: 10.18632/oncotarget.16235.
9. Nahi H., Chrobok M., Gran C. et al. Infectious complications and NK cell depletion following daratumumab treatment of multiple myeloma. PLoS One 2019;14(2):e0211927. DOI: 10.1371/journal.pone.0211927.
10. Terpos E., Ntanasis-Stathopoulos I., Elalamy I. et al. Hematological findings and complications of COVID-19. Am J Hematol 2020. DOI: 10.1002/ajh.25829.
11. COVID-19: Collaboration and Resilience Are Paying Off (March 26, 2020 UPDATE). International Myeloma Foundation (IMF), 2020. Available at: https://www.myeloma.org/drdurie-blog/covid-19-collaboration-resilience-arepaying-march-26-2020-update (access date 22.05.2020).
12. ESMO management and treatment adapted recommendations in the COVID-19 era: multiple myeloma. European Society for Medical Oncology (ESMO), 2020. Available at: https://www.esmo.org/guidelines/cancer-patient-managementduring-the-covid-19-pandemic/haematological-malignancies-multiplemyeloma-in-the-covid-19-era (access date 22.05.2020).
13. International Myeloma Society Recommendations for the Management of Myeloma Patients During the COVID-19 Pandemic. International Myeloma Society (IMS), 2020. Available at: https://cms.cws.net/content/beta.myelomasociety.org/files/IMS%20recommendations%20for%20Physicians%20Final.pdf (access date 22.05.2020).
14. COVID-19 and Multiple Myeloma: Frequently Asked Questions. American Society of Hematology (ASH), 2020. Available at: https://www.hematology.org/covid-19/covid-19-and-multiple-myeloma (access date 22.05.2020).
15. Российские клинические рекомендации по диагностике и лечению лимфопролиферативных заболеваний: монография. Под ред.: И.В. Поддубной, В.Г. Савченко. М.: Российское профессиональное общество онкогематологов, 2018. 356 с.
16. Avet-Loiseau H., Bahlis N.J., Chng W.J. Ixazomib significantly prolongs progression-free survival in high-risk relapsed/refractory myeloma patients. Blood 2017;130(24):2610–8. DOI: 10.1182/blood-2017-06-791228.
